BHVN
Biohaven Pharmaceutical Holding Co LtdNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.38B
P/E Ratio
—
EPS
$-6.86
Beta
3.62
52W High
$24.06
52W Low
$7.48
50-Day MA
$10.65
200-Day MA
$12.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Biohaven Pharmaceutical Holding Co Ltd
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-698.45M |
| Operating Margin | 0.00% |
| Return on Equity | -310.70% |
| Return on Assets | -83.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.39 |
| Price-to-Book | 28.31 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $150.42M |
| Float | $123.89M |
| % Insiders | 11.09% |
| % Institutions | 91.46% |
Analyst Ratings
Consensus ($22.44 target)
4
Strong Buy9
Buy5
HoldData last updated: 4/7/2026